Amylin (AMLN) and Eli Lilly (LLY) Report First Head-to-Head Results Showing BYETTA(R) Provides Greater Reduction in Post-Meal Glucose Levels Than Januvia(TM)
More News related to AMLN
- Unusual 11 Mid-Day Movers 11/17: GTE, CTS, PHH, ARTG Higher; UTHR, DFT, BIDU, HIG Lower
- Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
- Canaccord Adams Maintains 'Hold' Rating on Amylin Pharmaceuticals (AMLN), Lowers Price Target
- Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
- Amylin Pharma (AMLN) Sees Morning Pressure
More News related to LLY
- Lilly Completes Cash Tender Offer for ImClone Systems
- Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center
- Lilly Selects ICON to Manage its Clinical Data Management Business Outside the US
- ImClone Systems Announces Clearance of Tender Offer by German Federal Cartel Office
- Eli Lilly (LLY) In License and Supply Agreement With United Therapeutics (UTHR)
More News related to Corporate News
- Solars Rise as Merrill Downgrades First Solar (FSLR), SunPower (SPWRA)
- Merrill Lynch Downgrades Autodesk (ADSK) to Underperform
- Friedman Billings Downgrades Goodrich (GR) to Market Perform
- Friedman Billings Downgrades Spirit AeroSystems (SPR) to Market Perform
- Friedman Billings Downgrades BE Aerospace (BEAV) to Market Perform
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly (NYSE: LLY) today announced results from a randomized, double-blind, cross-over, four-week head-to-head study demonstrating that BYETTA(R) injection, a GLP-1 receptor agonist, provided significantly lower glucose levels in the post-meal setting when compared to Januvia(TM), a DPP-4 inhibitor. Additionally, patients treated with BYETTA reduced post-meal glucagon, showed more efficient use of their body's own insulin and decreased their food intake when compared to Januvia.
This is the first reported head-to-head study directly comparing the therapeutic mechanisms of action of BYETTA and Januvia. The findings were presented at the 44th Annual Meeting of the European Association for the Study of Diabetes in Rome, Italy.
The primary endpoint of this four-week study compared the effect of BYETTA and Januvia on 2-hour post-meal glucose. Secondary endpoints included post-meal glucagon, insulin secretion rate, gastric emptying, and food intake. Patients were randomly assigned to treatment with either BYETTA (5 mcg twice daily for the first week followed by 10 mcg twice daily for the second week) or Januvia (100 mg once daily) for two weeks; patients were then switched to the alternate therapy for the remaining two weeks. At baseline and at the end of each two week treatment period, patients underwent a standard meal test and other evaluations to assess each drug's effects on various measures of post-meal glucose control, indicators of beta cell function and other parameters.
Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States.
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide.
Related Categories
Corporate NewsStocks Mentioned
-0.49Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
